Legend Biotech (LEGN) Income towards Parent Company (2019 - 2025)
Legend Biotech (LEGN) posted Income towards Parent Company of -$8.4 million for Q4 2025, up 78.16% quarter-over-quarter from -$38.5 million in Q3 2025, and down 12000000100.0% year-on-year from N/an in Q4 2024.
Legend Biotech (LEGN) Income towards Parent Company (2019 - 2025) Analysis & Trends
Legend Biotech (LEGN) has reported Income towards Parent Company for 7 consecutive years, with -$8.4 million the latest figure, recorded in Q4 2025.
- Income towards Parent Company for Q4 2025 came in at -$8.4 million, down 12000000100.0% year-over-year; the trailing twelve-month figure through Dec 2025 was -$171.1 million (down 27154444266.16% YoY), and the FY2025 annual result was -$268.4 million, down 55916666566.67% from the prior year.
- Income towards Parent Company was -$8.4 million for Q4 2025 at Legend Biotech, up from -$38.5 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $172.6 million in Q2 2021 and troughed at -$124.8 million in Q3 2021.
- Average Income towards Parent Company over 5 years is -$10.6 million, with a median of -$0.22 recorded in 2025.
- Year-over-year, Income towards Parent Company jumped 227.95% in 2021 and sank 33571891991.89% in 2025.
- Over 5 years, Income towards Parent Company stood at -$88.3 million in 2021, then surged by 100.0% to -$0.41 in 2022, then increased by 2.44% to -$0.4 in 2023, then surged by 117.5% to $0.07 in 2024, then slumped by 12000000100.0% to -$8.4 million in 2025.
- Per Business Quant data, the three most recent Income towards Parent Company figures were -$8.4 million in Q4 2025, -$38.5 million in Q3 2025, and -$124.2 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - |
| 10 | Legend Biotech | 11.04 Bn | 10.14 Bn | 242.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -8.50 Mn |
| Sep 30, 2025 | -38.46 Mn |
| Jun 30, 2025 | -124.22 Mn |
| Mar 31, 2025 | -0.27 |
| Dec 31, 2024 | 26,284.00 |
| Sep 30, 2024 | 0.35 |
| Jun 30, 2024 | 0.37 |
| Mar 31, 2024 | -0.16 |
| Dec 31, 2023 | -144,818.00 |
| Sep 30, 2023 | 0.16 |
| Jun 30, 2023 | 1.25 |
| Mar 31, 2023 | -0.34 |
| Dec 31, 2022 | -0.41 |
| Sep 30, 2022 | 260.00 |
| Jun 30, 2022 | 730.10 |
| Mar 31, 2022 | -0.10 |
| Dec 31, 2021 | -88.33 Mn |
| Sep 30, 2021 | -124.75 Mn |
| Jun 30, 2021 | 172.57 Mn |
| Mar 31, 2021 | -90,521.00 |